Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ROZANOLIXIZUMAB-NOLI: Who Reports Side Effects? Age, Gender & Country Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

Gender Distribution

63.3%
Female
36.7%
Male

Age Information

The average age of patients reporting adverse events with ROZANOLIXIZUMAB-NOLI is 55.1 years.

Geographic Distribution

The majority of adverse event reports for ROZANOLIXIZUMAB-NOLI originate from US.

Report Summary & Outcomes

349
Total Reports
349
As Primary/Secondary Suspect
4
Deaths Reported
84
Hospitalizations
5
Life-Threatening
2
Disabilities

Reporting Timeline

First adverse event report: 20230101. Most recent report: 20250805. View full timeline →

More About ROZANOLIXIZUMAB-NOLI

ROZANOLIXIZUMAB-NOLI Full Profile Reports by Year Drug Interactions